NeuroDerm (NDRM) Updates on End-of-Phase 2 FDA Meeting; Will Discontinue ND0612H Phase 3, Suspend iNDiGO
Tweet Send to a Friend
NeuroDerm Ltd. (Nasdaq: NDRM) announced that following its End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
